Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewGAMS
Discontinued Product
GAMS (Cat. No. 0150) has been withdrawn from sale for commercial reasons.
Description: Non-NMDA antagonist
Chemical Name: g-D-Glutamylaminomethylsulfonic acid
Biological Activity for GAMS
Historic kainate/quisqualate selective antagonist; may be able to distinguish between AMPA and kainate receptors. Anticonvulsant.
Technical Data for GAMS
| M. Wt | 240.23 |
| Storage | Store at RT |
| CAS Number | 90237-02-8 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for GAMS
Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service
Please contact Customer Service
References for GAMS
References are publications that support the biological activity of the product.
Croucher et al (1984) γ-D-Glutamylaminomethylsulphonic acid (GAMS), a kainate and quisqualate antagonist, prevents sound-induced seizures in DBA/2 mice. Brain Res. 322 111 PMID: 6097331
Wilding and Huettner (1996) Antagonist pharmacology of kainate- and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring receptors. Mol.Pharmacol. 49 540 PMID: 8643094
Zhou et al (1993) γ-D-Glutamylaminomethyl sulfonic acid (GAMS) distinguishes kainic acid- from AMPA-induced response in Xenopus oocytes expressing chick brain glutamate receptors. Neuropharmacology 32 767 PMID: 7692340
View Related Products by Target
View Related Products by Product Action
Keywords: GAMS, GAMS supplier, Non-selective, Ionotropic, Glutamate, 0150, Tocris Bioscience
Citations for GAMS
Citations are publications that use Tocris products.
Currently there are no citations for GAMS.
Reviews for GAMS
There are currently no reviews for this product. Be the first to review GAMS and earn rewards!
Have you used GAMS?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Ion Channel Product Listing
A collection of around 500 products for ion channel research, the listing includes research tools for the study of:
- Ligand-gated ion channels
- Voltage-gated ion channels
- Other Ion Channels
Pain Research Product Guide
A collection of over 280 products for pain research, the guide includes research tools for the study of:
- Nociception
- Ion Channels
- G-Protein-Coupled Receptors
- Intracellular Signaling
Epilepsy Poster
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Pain Poster
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.